Index -
P/E -
EPS (ttm) -8.92
Insider Own 29.16%
Shs Outstand 5.48M
Perf Week 7.29%
Market Cap 113.09M
Forward P/E -
EPS next Y -7.45
Insider Trans -0.04%
Shs Float 4.50M
Perf Month 26.76%
Income -45.61M
PEG -
EPS next Q -2.36
Inst Own 18.52%
Short Float 0.36%
Perf Quarter 15.72%
Sales 21.48M
P/S 5.27
EPS this Y 41.70%
Inst Trans -23.96%
Short Ratio 1.00
Perf Half Y 46.34%
Book/sh 5.47
P/B 3.26
EPS next Y 4.55%
ROA -50.15%
Short Interest 0.02M
Perf Year 64.91%
Cash/sh 17.20
P/C 1.04
EPS next 5Y 17.00%
ROE -101.78%
52W Range 7.69 - 20.04
Perf YTD 80.97%
Dividend Est. -
P/FCF 4.69
EPS past 5Y 22.47%
ROI -129.82%
52W High -11.13%
Beta 0.63
Dividend TTM -
Quick Ratio 2.74
Sales past 5Y 42.26%
Gross Margin 98.77%
52W Low 131.54%
ATR (14) 1.06
Dividend Ex-Date -
Current Ratio 2.74
EPS Y/Y TTM 54.42%
Oper. Margin -235.24%
RSI (14) 65.97
Volatility 6.75% 6.08%
Employees 65
Debt/Eq 0.05
Sales Y/Y TTM -100.00%
Profit Margin -212.33%
Recom 2.00
Target Price 36.00
Option/Short No / Yes
LT Debt/Eq 0.01
EPS Q/Q 49.06%
Payout -
Rel Volume 1.88
Prev Close 18.07
Sales Surprise 42.22%
EPS Surprise 11.21%
Sales Q/Q -
Earnings Aug 08 AMC
Avg Volume 16.11K
Price 17.81
SMA20 10.86%
SMA50 18.76%
SMA200 36.55%
Trades
Volume 26,047
Change -1.44%
Date
Action
Analyst
Rating Change
Price Target Change
Sep-13-21 Initiated
H.C. Wainwright
Neutral
$3.50
Sep-02-21 Downgrade
William Blair
Outperform → Mkt Perform
Mar-23-21 Downgrade
SVB Leerink
Outperform → Mkt Perform
Nov-06-20 Downgrade
Jefferies
Buy → Hold
$30 → $10
Oct-19-20 Initiated
Truist
Buy
$55
Oct-16-19 Initiated
Mizuho
Buy
$20
Nov-19-18 Initiated
Leerink Partners
Outperform
$45
Oct-08-18 Upgrade
B. Riley FBR
Neutral → Buy
$42
Aug-08-18 Initiated
Robert W. Baird
Outperform
$74
Apr-13-18 Downgrade
Chardan Capital Markets
Buy → Neutral
$35 → $50
Jan-05-18 Initiated
B. Riley FBR, Inc.
Neutral
$35
Nov-08-17 Initiated
Jefferies
Buy
$50
May-30-17 Initiated
Chardan Capital Markets
Buy
$35
Show Previous Ratings
Today 09:40AM
Aug-08-24 05:22PM
(Associated Press Finance) +6.02%
04:05PM
Jul-15-24 08:00AM
Jun-18-24 08:00AM
08:00AM
Loading…
Jun-17-24 08:00AM
Jun-10-24 08:00AM
Jun-05-24 08:00AM
May-22-24 08:00AM
May-13-24 08:53AM
May-09-24 05:04AM
(Associated Press Finance)
May-08-24 04:05PM
Mar-28-24 10:53PM
04:05PM
Mar-25-24 12:52PM
08:00AM
Loading…
Feb-08-24 08:00AM
Jan-04-24 08:00AM
Nov-10-23 04:05PM
08:00AM
Nov-08-23 05:08PM
(Associated Press Finance)
-12.48%
04:05PM
08:00AM
Oct-17-23 10:59AM
07:00AM
Oct-11-23 08:00AM
Oct-02-23 08:00AM
Sep-19-23 04:05PM
Aug-09-23 06:11PM
(Associated Press Finance)
04:05PM
Jul-17-23 08:00AM
08:00AM
Loading…
Jun-21-23 08:00AM
Jun-07-23 08:00AM
May-23-23 04:05PM
May-04-23 06:28PM
04:05PM
Apr-18-23 08:00AM
Mar-30-23 10:04AM
(Simply Wall St.) -10.11%
Mar-22-23 04:05PM
Feb-15-23 08:00AM
Dec-19-22 03:19PM
08:00AM
Nov-14-22 08:00AM
Nov-09-22 09:35AM
Nov-08-22 04:05PM
Nov-04-22 08:00AM
Oct-24-22 08:00AM
Oct-21-22 09:36AM
Oct-05-22 04:05PM
Aug-24-22 08:00AM
Aug-09-22 04:05PM
Aug-04-22 12:00PM
10:00AM
06:27AM
Jul-21-22 07:22AM
06:26AM
Jul-20-22 05:48PM
(American City Business Journals)
04:05PM
Jun-22-22 08:00AM
07:00AM
Jun-21-22 08:00AM
Jun-08-22 08:00AM
07:58AM
Jun-06-22 08:00AM
Jun-03-22 04:05PM
May-27-22 09:38AM
May-25-22 11:06AM
(American City Business Journals)
May-12-22 04:05PM
(GlobeNewswire) +7.41%
+6.21%
Apr-01-22 05:00PM
Mar-23-22 04:19PM
Mar-21-22 08:00AM
Mar-10-22 04:05PM
Feb-09-22 08:00AM
Jan-19-22 09:38PM
Jan-07-22 05:00PM
Jan-06-22 08:00AM
Jan-04-22 08:00AM
Dec-07-21 10:00AM
Dec-03-21 05:00PM
Nov-12-21 08:00AM
Nov-04-21 04:05PM
Nov-01-21 10:32AM
Oct-19-21 07:30AM
Oct-06-21 08:00AM
Oct-01-21 06:04PM
Sep-24-21 06:35AM
Sep-02-21 03:18PM
12:05PM
10:17AM
06:49AM
Sep-01-21 04:02PM
Aug-18-21 08:00AM
Aug-05-21 05:45PM
04:01PM
Aug-03-21 08:00AM
Jul-28-21 03:03PM
Jul-20-21 08:00AM
Jul-02-21 05:00PM
Jun-26-21 03:26AM
Jun-23-21 08:00AM
Jun-09-21 08:00AM
Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
White Nicole S Chief Manufacturing Officer Aug 02 '24 Sale 14.23 785 11,173 12,068 Aug 05 04:10 PM Okazaki Jason A CEO and President Aug 02 '24 Sale 14.23 981 13,962 15,101 Aug 05 04:05 PM Schornstein Alexander 10% Owner Jul 03 '24 Buy 12.29 4,562 56,067 688,675 Jul 08 10:48 AM Schornstein Alexander 10% Owner Jul 05 '24 Buy 12.52 4,438 55,564 693,113 Jul 08 10:48 AM Bjorkquist Jeanette M Principal Accounting Officer May 23 '24 Sale 14.93 24 358 3,142 May 24 04:10 PM McHutchison John G Director May 23 '24 Sale 14.93 2,117 31,615 19,104 May 24 04:10 PM White Nicole S Chief Manufacturing Officer May 23 '24 Sale 14.93 172 2,569 12,853 May 24 04:05 PM Okazaki Jason A CEO and President May 23 '24 Sale 14.93 549 8,199 16,082 May 24 04:05 PM White Nicole S Chief Manufacturing Officer Apr 30 '24 Sale 12.71 1,255 15,947 13,025 May 01 04:10 PM Okazaki Jason A CEO and President Apr 30 '24 Sale 12.71 1,569 19,937 16,423 May 01 04:05 PM McHutchison John G Director Apr 01 '24 Sale 13.07 1,206 15,765 21,221 Apr 02 04:25 PM Bjorkquist Jeanette M Principal Accounting Officer Apr 01 '24 Sale 13.07 114 1,490 3,166 Apr 02 04:20 PM White Nicole S Chief Manufacturing Officer Apr 01 '24 Sale 13.07 197 2,575 10,947 Apr 02 04:15 PM Okazaki Jason A CEO and President Apr 01 '24 Sale 13.07 354 4,627 13,826 Apr 02 04:05 PM Okazaki Jason A CEO and President Mar 27 '24 Sale 12.87 392 5,045 14,180 Mar 29 04:05 PM Schornstein Alexander 10% Owner Jan 18 '24 Buy 0.80 345,086 276,069 8,209,372 Jan 19 11:01 AM Schornstein Alexander 10% Owner Jan 17 '24 Buy 0.78 299,994 235,195 7,864,286 Jan 19 11:01 AM Schornstein Alexander 10% Owner Nov 20 '23 Buy 0.72 300,000 215,400 7,464,292 Nov 22 04:10 PM Schornstein Alexander 10% Owner Nov 21 '23 Buy 0.67 100,000 66,700 7,564,292 Nov 22 04:10 PM White Nicole S Chief Manufacturing Officer Nov 17 '23 Sale 0.69 477 329 93,774 Nov 21 04:05 PM White Nicole S Chief Manufacturing Officer Oct 03 '23 Sale 0.80 1,891 1,504 94,251 Oct 04 04:15 PM Delaney William E IV Chief Scientific Officer Oct 03 '23 Sale 0.80 1,891 1,504 150,853 Oct 04 04:10 PM Okazaki Jason A CEO and President Oct 03 '23 Sale 0.80 2,363 1,879 174,923 Oct 04 04:05 PM
Index -
P/E -
EPS (ttm) -2.11
Insider Own 38.97%
Shs Outstand 27.61M
Perf Week 4.83%
Market Cap 36.85M
Forward P/E -
EPS next Y -0.58
Insider Trans 2.92%
Shs Float 26.83M
Perf Month 1.02%
Income -65.53M
PEG -
EPS next Q -0.25
Inst Own 15.15%
Short Float 0.12%
Perf Quarter -17.79%
Sales 2.36M
P/S 15.62
EPS this Y 54.80%
Inst Trans -3.75%
Short Ratio 0.22
Perf Half Y 22.41%
Book/sh 0.76
P/B 1.10
EPS next Y 54.11%
ROA -71.92%
Short Interest 0.03M
Perf Year -66.99%
Cash/sh 1.71
P/C 0.49
EPS next 5Y -
ROE -130.03%
52W Range 0.49 - 2.89
Perf YTD 52.45%
Dividend Est. -
P/FCF -
EPS past 5Y -44.91%
ROI -159.90%
52W High -71.02%
Beta -0.06
Dividend TTM -
Quick Ratio 2.02
Sales past 5Y 0.00%
Gross Margin 23.76%
52W Low 71.12%
ATR (14) 0.09
Dividend Ex-Date -
Current Ratio 2.02
EPS Y/Y TTM 31.42%
Oper. Margin -2830.04%
RSI (14) 49.07
Volatility 13.63% 11.36%
Employees 73
Debt/Eq 0.26
Sales Y/Y TTM -
Profit Margin -2780.27%
Recom 1.33
Target Price 5.50
Option/Short No / Yes
LT Debt/Eq 0.23
EPS Q/Q 65.78%
Payout -
Rel Volume 0.08
Prev Close 0.82
Sales Surprise -92.14%
EPS Surprise -4.35%
Sales Q/Q -
Earnings Aug 08 BMO
Avg Volume 138.65K
Price 0.84
SMA20 -0.63%
SMA50 -6.63%
SMA200 -5.49%
Trades
Volume 9,033
Change 2.26%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-21-22 Initiated
Chardan Capital Markets
Buy
$7
Jan-10-22 Initiated
H.C. Wainwright
Buy
$36
Nov-16-21 Initiated
Raymond James
Outperform
$31
Nov-16-21 Initiated
Morgan Stanley
Overweight
$32
Nov-16-21 Initiated
Guggenheim
Buy
$40
Nov-16-21 Initiated
Cowen
Outperform
Aug-28-24 04:01PM
Aug-08-24 07:30AM
Jun-13-24 04:05PM
May-29-24 06:05AM
(Pharmaceutical Technology)
May-14-24 01:54PM
07:30AM
Loading…
07:30AM
Apr-16-24 09:14AM
Apr-01-24 10:53PM
04:05PM
Mar-28-24 11:10AM
07:05AM
07:00AM
06:45AM
Feb-28-24 04:01PM
(GlobeNewswire) +5.60%
+7.42%
Jan-31-24 04:01PM
07:30AM
Loading…
Jan-08-24 07:30AM
Dec-07-23 07:30AM
Nov-09-23 04:01PM
(GlobeNewswire) -13.04%
-10.63%
Nov-03-23 12:00PM
Oct-31-23 09:15AM
Sep-27-23 05:02PM
Sep-05-23 08:30AM
07:30AM
Aug-18-23 04:27AM
(Thomson Reuters StreetEvents)
Aug-14-23 07:30AM
Aug-03-23 04:05PM
May-25-23 05:01PM
May-09-23 07:30AM
Apr-03-23 04:05PM
Mar-02-23 04:05PM
07:30AM
Loading…
Feb-27-23 07:30AM
Feb-16-23 07:30AM
Feb-02-23 07:30AM
Jan-26-23 05:30AM
Jan-25-23 09:45AM
Nov-23-22 07:30AM
Nov-09-22 07:30AM
Nov-04-22 07:30AM
Sep-22-22 04:05PM
Sep-15-22 04:05PM
Sep-06-22 04:05PM
Aug-11-22 09:41AM
Aug-09-22 07:30AM
Jun-16-22 07:30AM
May-18-22 07:30AM
May-17-22 07:30AM
May-12-22 07:30AM
Apr-07-22 06:30AM
Mar-01-22 06:30AM
Feb-28-22 06:30AM
Feb-07-22 05:38PM
Feb-03-22 06:30AM
Jan-25-22 10:27AM
Jan-20-22 07:30AM
Jan-06-22 07:30AM
Dec-02-21 07:30AM
Nov-12-21 07:00AM
Oct-27-21 07:45AM
Oct-26-21 04:05PM
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
GILEAD SCIENCES, INC. 10% Owner Apr 02 '24 Buy 0.76 485,250 368,790 7,345,473 Apr 03 06:50 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 733 469 2,019,563 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Feb 08 '24 Sale 0.64 267 171 734,546 Feb 09 04:33 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 1,566 1,362 2,021,836 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 1,540 1,278 2,020,296 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 11 '24 Sale 0.87 569 495 735,373 Jan 16 06:16 PM Atlas Venture Fund XI, L.P. 10% Owner Jan 12 '24 Sale 0.83 560 465 734,813 Jan 16 06:16 PM
Index RUT
P/E -
EPS (ttm) -2.63
Insider Own 59.03%
Shs Outstand 43.12M
Perf Week -7.05%
Market Cap 296.01M
Forward P/E -
EPS next Y -4.00
Insider Trans 0.00%
Shs Float 17.68M
Perf Month -1.44%
Income -91.63M
PEG -
EPS next Q -0.76
Inst Own 37.38%
Short Float 15.17%
Perf Quarter -28.02%
Sales 0.00M
P/S -
EPS this Y 96.28%
Inst Trans -
Short Ratio 4.57
Perf Half Y -76.91%
Book/sh 7.73
P/B 0.89
EPS next Y -19.96%
ROA -
Short Interest 2.68M
Perf Year -
Cash/sh 8.02
P/C 0.85
EPS next 5Y -
ROE -
52W Range 6.30 - 35.06
Perf YTD -77.13%
Dividend Est. -
P/FCF -
EPS past 5Y -
ROI -26.98%
52W High -80.43%
Beta -
Dividend TTM -
Quick Ratio 14.86
Sales past 5Y -37.90%
Gross Margin -
52W Low 8.89%
ATR (14) 0.61
Dividend Ex-Date -
Current Ratio 14.86
EPS Y/Y TTM -
Oper. Margin 0.00%
RSI (14) 39.80
Volatility 6.25% 7.93%
Employees 96
Debt/Eq 0.03
Sales Y/Y TTM -
Profit Margin -
Recom 1.40
Target Price 41.25
Option/Short Yes / Yes
LT Debt/Eq 0.02
EPS Q/Q -119.89%
Payout -
Rel Volume 0.63
Prev Close 7.20
Sales Surprise -
EPS Surprise 4.05%
Sales Q/Q -
Earnings Aug 12 AMC
Avg Volume 586.95K
Price 6.86
SMA20 -9.29%
SMA50 -15.17%
SMA200 -56.24%
Trades
Volume 319,981
Change -4.72%
Date
Action
Analyst
Rating Change
Price Target Change
Jul-03-24 Initiated
H.C. Wainwright
Neutral
$8
Mar-04-24 Initiated
Wells Fargo
Overweight
$44
Mar-04-24 Initiated
Morgan Stanley
Overweight
$40
Mar-04-24 Initiated
Leerink Partners
Outperform
$48
Mar-04-24 Initiated
JP Morgan
Overweight
$39
Today 08:00AM
06:58AM
Aug-21-24 04:05PM
(PR Newswire) +13.36%
-5.36%
Aug-12-24 04:08PM
04:05PM
11:33AM
Loading…
Jul-16-24 11:33AM
(Pharmaceutical Technology) +11.71%
08:52AM
Jul-15-24 04:05PM
Jun-20-24 08:55AM
Jun-17-24 04:05PM
(PR Newswire) -17.21%
-5.70%
Jun-10-24 04:05PM
Jun-07-24 08:55AM
May-14-24 10:54PM
04:05PM
Apr-11-24 05:01PM
02:59PM
Loading…
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
(The Wall Street Journal)
Mar-07-24 07:26PM
06:14PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Walker Karen Marie Chief Technology Officer Jun 06 '24 Option Exercise 4.42 9,636 42,591 9,636 Jun 10 06:56 PM Jones Ryan Alexander Chief Financial Officer May 28 '24 Option Exercise 0.73 18,016 13,152 43,950 May 29 04:33 PM Vida Ventures, LLC 10% Owner Feb 12 '24 Buy 22.00 253,136 5,568,992 252,553 Feb 14 07:04 PM Bain Capital Life Sciences Inv 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 3,163,868 Feb 14 05:26 PM GILEAD SCIENCES, INC. 10% Owner Feb 12 '24 Buy 22.00 910,000 20,020,000 4,126,119 Feb 13 05:48 PM Northpond Ventures III GP, LLC Former 10% Owner Feb 12 '24 Buy 22.00 450,000 9,900,000 450,000 Feb 12 05:51 PM
Index RUT
P/E -
EPS (ttm) -3.10
Insider Own 46.71%
Shs Outstand 75.50M
Perf Week 4.05%
Market Cap 1.55B
Forward P/E -
EPS next Y -4.63
Insider Trans -0.06%
Shs Float 48.72M
Perf Month 7.88%
Income -249.00M
PEG -
EPS next Q -1.00
Inst Own 54.18%
Short Float 13.83%
Perf Quarter 0.00%
Sales 247.00M
P/S 6.28
EPS this Y 24.38%
Inst Trans -0.66%
Short Ratio 9.99
Perf Half Y -10.59%
Book/sh 6.96
P/B 2.44
EPS next Y -47.40%
ROA -20.70%
Short Interest 6.74M
Perf Year -16.20%
Cash/sh 10.60
P/C 1.60
EPS next 5Y 7.80%
ROE -41.47%
52W Range 12.95 - 20.94
Perf YTD -11.15%
Dividend Est. -
P/FCF -
EPS past 5Y -23.70%
ROI -39.21%
52W High -18.96%
Beta 0.88
Dividend TTM -
Quick Ratio 5.14
Sales past 5Y 164.80%
Gross Margin 94.74%
52W Low 31.04%
ATR (14) 0.94
Dividend Ex-Date -
Current Ratio 5.14
EPS Y/Y TTM 21.51%
Oper. Margin -110.53%
RSI (14) 53.07
Volatility 5.71% 5.44%
Employees 577
Debt/Eq 0.02
Sales Y/Y TTM 103.73%
Profit Margin -100.81%
Recom 1.50
Target Price 33.12
Option/Short Yes / Yes
LT Debt/Eq 0.00
EPS Q/Q 0.36%
Payout -
Rel Volume 0.54
Prev Close 17.95
Sales Surprise 48.65%
EPS Surprise 8.52%
Sales Q/Q 34.48%
Earnings Aug 08 AMC
Avg Volume 674.09K
Price 16.97
SMA20 -0.51%
SMA50 7.58%
SMA200 3.05%
Trades
Volume 312,206
Change -5.46%
Date
Action
Analyst
Rating Change
Price Target Change
Nov-18-22 Initiated
BofA Securities
Neutral
$33
Oct-11-22 Initiated
Morgan Stanley
Overweight
$40
Oct-15-21 Resumed
BTIG Research
Buy
$57
Nov-24-20 Initiated
Berenberg
Buy
$50
Nov-23-20 Initiated
Evercore ISI
Outperform
Apr-03-20 Initiated
Cantor Fitzgerald
Overweight
$21
Mar-04-20 Initiated
Barclays
Overweight
$24
Nov-12-19 Initiated
SunTrust
Buy
$20
Sep-27-19 Initiated
Mizuho
Buy
$22
May-24-19 Resumed
Citigroup
Buy
$25
Oct-09-18 Initiated
Wedbush
Outperform
$22
Apr-09-18 Initiated
Leerink Partners
Outperform
$21
Apr-09-18 Initiated
Goldman
Neutral
$18
Apr-09-18 Initiated
Citigroup
Buy
$18
Show Previous Ratings
Sep-10-24 04:35PM
Aug-28-24 02:33PM
(Pharmaceutical Technology)
Aug-27-24 04:05PM
Aug-26-24 04:35PM
Aug-21-24 04:05PM
04:52AM
Loading…
Aug-16-24 04:52AM
(Pharmaceutical Technology)
Aug-08-24 06:15PM
04:05PM
Aug-01-24 10:01AM
08:00AM
Jul-25-24 04:05PM
Jul-09-24 04:35PM
06:32AM
(Pharmaceutical Technology)
Jul-08-24 06:00PM
Jun-25-24 04:35PM
04:35PM
Loading…
Jun-11-24 04:35PM
Jun-10-24 08:30AM
Jun-07-24 10:55AM
Jun-06-24 04:05PM
Jun-02-24 08:00AM
Jun-01-24 08:00AM
May-24-24 04:35PM
May-10-24 01:38PM
May-09-24 04:35PM
03:48PM
03:47AM
May-08-24 09:59PM
05:45PM
04:02PM
May-02-24 04:05PM
10:01AM
Loading…
May-01-24 10:01AM
Apr-24-24 04:00PM
Apr-23-24 04:05PM
Apr-09-24 04:35PM
Mar-29-24 07:01PM
Mar-26-24 04:35PM
Mar-20-24 07:00PM
Mar-11-24 04:35PM
Feb-29-24 03:14AM
Feb-28-24 04:05PM
Feb-27-24 04:35PM
Feb-22-24 11:10AM
09:55AM
07:16AM
(Thomson Reuters StreetEvents)
Feb-21-24 04:37PM
04:05PM
Feb-09-24 04:35PM
Feb-07-24 05:00PM
Feb-05-24 12:59PM
Jan-29-24 05:00PM
Jan-26-24 04:35PM
Jan-16-24 05:00PM
Dec-11-23 04:35PM
Dec-04-23 08:00AM
Nov-27-23 04:35PM
Nov-14-23 04:00PM
Nov-13-23 04:35PM
Nov-08-23 04:05PM
Nov-07-23 04:01PM
Nov-06-23 05:00PM
Oct-31-23 10:01AM
Oct-24-23 04:35PM
Oct-17-23 04:00PM
Oct-10-23 04:35PM
Sep-27-23 05:14AM
Sep-26-23 04:35PM
Sep-11-23 04:35PM
Sep-05-23 07:37PM
Aug-24-23 04:35PM
11:30AM
09:02AM
Aug-23-23 11:39AM
09:00AM
Aug-09-23 04:35PM
Aug-07-23 09:15AM
08:00AM
Aug-03-23 05:55PM
Aug-02-23 05:25PM
Aug-01-23 05:45PM
Jul-25-23 04:35PM
Jul-11-23 04:35PM
Jul-03-23 06:50AM
Jun-26-23 04:35PM
Jun-21-23 08:00PM
Jun-12-23 12:08PM
Jun-09-23 04:35PM
Jun-05-23 02:59PM
Jun-03-23 01:30PM
May-30-23 04:00PM
May-26-23 04:05PM
(Investor's Business Daily) +25.89%
10:27AM
(Investor's Business Daily)
May-24-23 04:35PM
May-17-23 08:30AM
May-16-23 11:51AM
09:31AM
May-15-23 08:30AM
May-11-23 09:44AM
09:33AM
07:44AM
May-09-23 06:15PM
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Azoy Alexander Chief Accounting Officer Aug 13 '24 Sale 14.97 1,357 20,314 19,070 Aug 15 04:45 PM Jarrett Jennifer Chief Operating Officer Mar 27 '24 Sale 17.55 11,551 202,720 215,253 Mar 29 04:20 PM Jarrett Jennifer Chief Operating Officer Mar 18 '24 Sale 17.92 13,449 240,941 226,804 Mar 20 04:19 PM Jarrett Jennifer Chief Operating Officer Feb 27 '24 Sale 20.11 34,070 685,148 240,253 Feb 28 07:55 PM Jarrett Jennifer Chief Operating Officer Feb 26 '24 Sale 20.07 24,555 492,819 274,323 Feb 28 07:55 PM Jaen Juan C. President Feb 27 '24 Sale 20.10 23,132 464,953 1,188,233 Feb 28 07:55 PM Jaen Juan C. President Feb 26 '24 Sale 20.06 3,900 78,234 1,211,365 Feb 28 07:55 PM GILEAD SCIENCES, INC. 10% Owner Jan 29 '24 Buy 21.00 15,238,095 319,999,995 30,061,124 Jan 31 05:00 PM Goeltz II Robert C. Chief Financial Officer Jan 02 '24 Sale 20.00 2,004 40,080 51,831 Jan 04 05:23 PM Jaen Juan C. President Jan 02 '24 Sale 20.09 6,975 140,128 1,215,265 Jan 04 05:22 PM Jarrett Jennifer Chief Operating Officer Dec 22 '23 Sale 17.76 21,521 382,213 258,878 Dec 26 04:04 PM Azoy Alexander Chief Accounting Officer Dec 01 '23 Sale 14.95 282 4,216 11,596 Dec 05 04:28 PM Jarrett Jennifer Chief Operating Officer Sep 22 '23 Sale 19.99 21,369 427,166 302,691 Sep 26 04:35 PM
Index -
P/E -
EPS (ttm) -1.23
Insider Own 49.61%
Shs Outstand 113.97M
Perf Week 2.23%
Market Cap 87.67M
Forward P/E -
EPS next Y -0.29
Insider Trans -0.18%
Shs Float 58.13M
Perf Month 4.02%
Income -140.34M
PEG -
EPS next Q -0.10
Inst Own 40.51%
Short Float 9.84%
Perf Quarter -0.16%
Sales 0.00M
P/S -
EPS this Y 72.86%
Inst Trans 24.76%
Short Ratio 18.52
Perf Half Y -2.43%
Book/sh 1.04
P/B 0.73
EPS next Y 41.61%
ROA -67.85%
Short Interest 5.72M
Perf Year -71.96%
Cash/sh 1.12
P/C 0.68
EPS next 5Y 29.50%
ROE -80.33%
52W Range 0.58 - 2.76
Perf YTD 11.80%
Dividend Est. -
P/FCF -
EPS past 5Y -70.96%
ROI -109.11%
52W High -72.46%
Beta 0.77
Dividend TTM -
Quick Ratio 55.08
Sales past 5Y -37.09%
Gross Margin -
52W Low 31.03%
ATR (14) 0.03
Dividend Ex-Date -
Current Ratio 55.08
EPS Y/Y TTM 32.62%
Oper. Margin 0.00%
RSI (14) 50.91
Volatility 4.40% 4.18%
Employees 112
Debt/Eq 0.07
Sales Y/Y TTM -
Profit Margin -
Recom 4.00
Target Price 0.80
Option/Short Yes / Yes
LT Debt/Eq 0.07
EPS Q/Q 88.96%
Payout -
Rel Volume 0.11
Prev Close 0.75
Sales Surprise -
EPS Surprise 51.50%
Sales Q/Q -
Earnings Aug 01
Avg Volume 308.89K
Price 0.76
SMA20 -0.04%
SMA50 0.14%
SMA200 -12.71%
Trades
Volume 29,563
Change 1.04%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-26-23 Downgrade
BofA Securities
Buy → Underperform
$17 → $1
Dec-22-23 Downgrade
Piper Sandler
Overweight → Neutral
Dec-22-23 Downgrade
Leerink Partners
Outperform → Market Perform
Dec-22-23 Downgrade
JP Morgan
Overweight → Underweight
Aug-18-23 Initiated
BofA Securities
Buy
$17
Oct-19-21 Resumed
Morgan Stanley
Overweight
$48
Aug-24-20 Initiated
SVB Leerink
Outperform
$41
Aug-24-20 Initiated
Morgan Stanley
Overweight
$49
Aug-24-20 Initiated
JP Morgan
Overweight
$50
Aug-09-24 02:52PM
May-14-24 08:53AM
Mar-18-24 03:53PM
Mar-13-24 11:53AM
10:00AM
05:50AM
Loading…
Mar-12-24 05:50AM
Mar-06-24 06:17PM
Mar-04-24 05:37PM
Feb-28-24 01:06AM
Feb-27-24 08:00AM
Feb-26-24 12:27PM
Feb-23-24 10:30AM
Jan-29-24 09:40AM
Jan-24-24 09:45AM
Jan-12-24 09:35AM
11:03AM
Loading…
Jan-05-24 11:03AM
08:37AM
Dec-26-23 10:04AM
Dec-22-23 09:31AM
08:30AM
07:10AM
07:00AM
Dec-05-23 08:55AM
Nov-16-23 07:00AM
Nov-02-23 10:04AM
07:00AM
Sep-21-23 02:44PM
Sep-14-23 09:59AM
Aug-28-23 07:00AM
Aug-03-23 07:00AM
07:17AM
Loading…
Jul-21-23 07:17AM
Jul-12-23 03:12AM
Jul-04-23 07:34AM
Jul-03-23 03:59AM
Jun-27-23 12:00PM
Jun-23-23 01:56PM
Jun-21-23 09:20PM
04:18PM
Jun-09-23 11:04AM
Jun-05-23 07:00AM
May-16-23 07:00AM
May-04-23 07:00AM
May-01-23 07:00AM
Apr-26-23 05:12PM
07:00AM
Mar-30-23 11:12AM
Feb-23-23 04:15PM
Feb-15-23 10:05AM
07:07AM
07:00AM
Feb-10-23 09:55AM
Feb-07-23 10:17AM
Feb-01-23 07:00AM
Jan-25-23 12:00PM
09:55AM
09:40AM
Jan-09-23 07:00AM
Jan-03-23 07:00AM
Dec-10-22 05:15PM
Nov-15-22 07:00AM
Nov-03-22 09:07AM
07:00AM
Oct-21-22 08:30AM
Sep-06-22 09:55AM
Aug-31-22 07:00AM
Aug-19-22 09:55AM
Aug-04-22 07:00AM
Aug-03-22 09:55AM
Aug-01-22 08:09AM
Jul-27-22 07:00AM
Jun-07-22 12:07PM
08:30AM
May-05-22 07:00AM
Apr-21-22 11:35AM
Apr-20-22 07:00AM
Apr-04-22 07:40PM
Mar-31-22 07:00AM
Mar-23-22 09:56AM
Mar-22-22 07:00AM
Feb-11-22 07:00AM
Feb-10-22 07:00AM
Jan-05-22 07:30AM
Jan-03-22 04:05PM
Dec-16-21 04:05PM
Dec-11-21 01:00PM
Nov-17-21 11:57AM
Nov-15-21 07:00AM
Nov-10-21 11:48AM
Nov-05-21 07:00AM
Oct-29-21 09:47AM
Oct-06-21 11:31AM
Oct-05-21 06:48AM
Oct-04-21 07:00AM
Sep-29-21 02:09PM
07:00AM
Sep-07-21 07:00AM
Sep-03-21 08:19AM
Aug-26-21 01:41PM
Aug-06-21 07:00AM
Jun-27-21 03:19AM
AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Brainard Diana Chief Executive Officer Aug 20 '24 Sale 0.74 5,390 3,996 753,923 Aug 22 04:15 PM Brainard Diana Officer Aug 20 '24 Proposed Sale 0.74 5,390 3,996 Aug 21 11:14 AM Miller Edward General Counsel Aug 19 '24 Sale 0.76 422 321 215,981 Aug 20 04:15 PM Sinha Vikas See Remarks Aug 19 '24 Sale 0.76 3,159 2,399 1,153,584 Aug 20 04:15 PM Hagen Brett R Chief Accounting Officer Aug 19 '24 Sale 0.76 544 413 71,981 Aug 20 04:15 PM Brainard Diana Chief Executive Officer Aug 19 '24 Sale 0.76 3,091 2,348 759,313 Aug 20 04:15 PM Sinha Vikas Owner Aug 19 '24 Proposed Sale 0.76 3,159 2,399 Aug 19 08:00 PM Brainard Diana Officer Aug 19 '24 Proposed Sale 0.76 3,091 2,348 Aug 19 08:00 PM Hagen Brett R Officer Aug 19 '24 Proposed Sale 0.76 544 413 Aug 19 08:00 PM Miller Edward Officer Aug 19 '24 Proposed Sale 0.76 422 321 Aug 19 08:00 PM Miller Edward General Counsel Aug 05 '24 Sale 0.73 2,323 1,707 216,403 Aug 07 04:15 PM Brainard Diana Chief Executive Officer Aug 05 '24 Sale 0.73 10,847 7,970 762,404 Aug 07 04:15 PM Sinha Vikas See Remarks Aug 05 '24 Sale 0.73 5,251 3,858 1,156,743 Aug 07 04:15 PM Hagen Brett R Chief Accounting Officer Aug 05 '24 Sale 0.73 1,692 1,243 72,525 Aug 07 04:15 PM Brainard Diana Officer Aug 05 '24 Proposed Sale 0.73 10,847 7,970 Aug 06 08:00 PM Sinha Vikas Owner Aug 05 '24 Proposed Sale 0.73 5,251 3,858 Aug 06 08:00 PM Hagen Brett R Officer Aug 05 '24 Proposed Sale 0.73 1,692 1,243 Aug 06 08:00 PM Miller Edward Officer Aug 05 '24 Proposed Sale 0.73 2,323 1,707 Aug 06 08:00 PM Hagen Brett R Chief Accounting Officer Jul 19 '24 Sale 0.75 479 359 74,698 Jul 23 04:28 PM Hagen Brett R Chief Accounting Officer Jul 22 '24 Sale 0.74 481 356 74,217 Jul 23 04:28 PM Brainard Diana Chief Executive Officer Jul 19 '24 Sale 0.75 9,731 7,299 773,251 Jul 23 04:28 PM Sinha Vikas See Remarks Jul 22 '24 Sale 0.74 1,858 1,373 1,161,994 Jul 23 04:27 PM Sinha Vikas See Remarks Jul 19 '24 Sale 0.75 1,542 1,157 1,163,852 Jul 23 04:27 PM Miller Edward General Counsel Jul 22 '24 Sale 0.74 757 560 218,726 Jul 23 04:25 PM Miller Edward General Counsel Jul 19 '24 Sale 0.75 634 476 219,483 Jul 23 04:25 PM Miller Edward General Counsel Jul 02 '24 Sale 0.72 379 273 220,117 Jul 03 04:14 PM Sinha Vikas See Remarks Jul 02 '24 Sale 0.72 939 676 1,165,394 Jul 03 04:14 PM Hagen Brett R Chief Accounting Officer Jul 02 '24 Sale 0.72 304 219 75,177 Jul 03 04:12 PM Brainard Diana Chief Executive Officer Jul 02 '24 Sale 0.72 1,489 1,072 782,982 Jul 03 04:11 PM Brainard Diana Chief Executive Officer May 21 '24 Sale 0.79 5,149 4,080 784,471 May 23 05:24 PM Hagen Brett R Chief Accounting Officer May 17 '24 Sale 0.75 541 405 75,481 May 21 04:35 PM Brainard Diana Chief Executive Officer May 17 '24 Sale 0.75 3,075 2,304 789,620 May 21 04:35 PM Sinha Vikas See Remarks May 17 '24 Sale 0.75 3,143 2,355 1,129,996 May 21 04:33 PM Miller Edward General Counsel May 17 '24 Sale 0.75 420 315 220,496 May 21 04:33 PM Brainard Diana Chief Executive Officer May 03 '24 Sale 0.80 10,240 8,151 792,695 May 07 04:15 PM Hagen Brett R Chief Accounting Officer May 03 '24 Sale 0.80 1,597 1,271 76,022 May 07 04:15 PM Sinha Vikas See Remarks May 03 '24 Sale 0.80 4,957 3,946 1,133,139 May 07 04:15 PM Miller Edward General Counsel May 03 '24 Sale 0.80 2,311 1,840 220,916 May 07 04:15 PM Hagen Brett R Chief Accounting Officer Apr 22 '24 Sale 0.75 480 360 77,619 Apr 23 04:15 PM Hagen Brett R Chief Accounting Officer Apr 19 '24 Sale 0.75 473 355 78,099 Apr 23 04:15 PM Miller Edward General Counsel Apr 22 '24 Sale 0.75 757 568 223,227 Apr 23 04:15 PM Miller Edward General Counsel Apr 19 '24 Sale 0.75 626 470 223,984 Apr 23 04:15 PM Brainard Diana Chief Executive Officer Apr 19 '24 Sale 0.75 9,601 7,207 802,935 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 22 '24 Sale 0.75 1,857 1,393 1,138,096 Apr 23 04:15 PM Sinha Vikas See Remarks Apr 19 '24 Sale 0.75 1,521 1,142 1,139,953 Apr 23 04:15 PM Miller Edward General Counsel Apr 02 '24 Sale 0.77 368 284 224,610 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Apr 02 '24 Sale 0.77 1,533 1,183 812,536 Apr 04 04:15 PM Hagen Brett R Chief Accounting Officer Apr 02 '24 Sale 0.77 281 217 78,572 Apr 04 04:15 PM Sinha Vikas See Remarks Apr 02 '24 Sale 0.77 885 683 1,141,474 Apr 04 04:15 PM Brainard Diana Chief Executive Officer Feb 21 '24 Sale 0.71 5,155 3,650 814,069 Feb 22 04:18 PM Brainard Diana Chief Executive Officer Feb 20 '24 Sale 0.70 3,097 2,153 819,224 Feb 22 04:18 PM Miller Edward General Counsel Feb 20 '24 Sale 0.70 385 268 224,978 Feb 22 04:16 PM Sinha Vikas See Remarks Feb 20 '24 Sale 0.70 2,893 2,011 1,142,359 Feb 22 04:15 PM Hagen Brett R Chief Accounting Officer Feb 20 '24 Sale 0.70 494 343 78,853 Feb 22 04:15 PM Hagen Brett R Chief Accounting Officer Feb 08 '24 Sale 0.67 11,150 7,494 79,347 Feb 09 08:01 PM Sinha Vikas See Remarks Feb 05 '24 Sale 0.67 18,331 12,282 1,145,252 Feb 06 04:46 PM Miller Edward General Counsel Feb 05 '24 Sale 0.67 8,869 5,942 225,363 Feb 06 04:40 PM Hagen Brett R Chief Accounting Officer Feb 05 '24 Sale 0.67 5,792 3,881 90,497 Feb 06 04:39 PM Brainard Diana Chief Executive Officer Feb 05 '24 Sale 0.67 41,421 27,752 822,321 Feb 06 04:38 PM Sinha Vikas See Remarks Jan 23 '24 Sale 0.67 3,205 2,150 1,163,583 Jan 25 04:15 PM Brainard Diana Chief Executive Officer Jan 23 '24 Sale 0.67 9,500 6,369 863,742 Jan 25 04:15 PM Hagen Brett R Chief Accounting Officer Jan 23 '24 Sale 0.67 901 604 96,289 Jan 25 04:15 PM Miller Edward General Counsel Jan 23 '24 Sale 0.67 1,302 873 234,232 Jan 25 04:15 PM Hagen Brett R Chief Accounting Officer Jan 04 '24 Sale 0.64 310 198 97,190 Jan 08 04:15 PM Miller Edward General Counsel Jan 04 '24 Sale 0.64 424 271 235,534 Jan 08 04:15 PM Sinha Vikas See Remarks Jan 04 '24 Sale 0.64 961 614 1,166,788 Jan 08 04:15 PM Brainard Diana Chief Executive Officer Jan 04 '24 Sale 0.64 1,664 1,063 873,242 Jan 08 04:15 PM Hagen Brett R Chief Accounting Officer Dec 27 '23 Sale 0.74 28,335 20,838 97,500 Jan 02 07:36 PM Sinha Vikas See Remarks Nov 17 '23 Sale 1.63 2,490 4,061 1,167,749 Nov 21 05:00 PM Brainard Diana Chief Executive Officer Nov 20 '23 Sale 1.69 4,382 7,408 874,906 Nov 21 05:00 PM Brainard Diana Chief Executive Officer Nov 17 '23 Sale 1.63 2,689 4,386 879,288 Nov 21 05:00 PM Hagen Brett R Chief Accounting Officer Nov 17 '23 Sale 1.63 403 657 125,835 Nov 21 05:00 PM Hagen Brett R Chief Accounting Officer Oct 19 '23 Sale 1.58 358 566 126,595 Oct 23 05:00 PM Hagen Brett R Chief Accounting Officer Oct 20 '23 Sale 1.54 357 550 126,238 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 19 '23 Sale 1.58 8,581 13,558 881,977 Oct 23 05:00 PM Sinha Vikas See Remarks Oct 20 '23 Sale 1.54 1,475 2,273 1,170,239 Oct 23 05:00 PM Sinha Vikas See Remarks Oct 19 '23 Sale 1.58 1,232 1,947 1,171,714 Oct 23 05:00 PM Brainard Diana Chief Executive Officer Oct 03 '23 Sale 1.98 1,325 2,619 890,558 Oct 05 05:00 PM Sinha Vikas See Remarks Oct 03 '23 Sale 1.98 755 1,492 1,172,946 Oct 05 05:00 PM Hagen Brett R Chief Accounting Officer Oct 03 '23 Sale 1.98 222 439 126,953 Oct 05 05:00 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite